Evidence map›Paper›PMID 24651679›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2014

Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection.

Iftach Shaked, David B Hanna, Christian Gleißner, Brenda Marsh, Jill Plants, Daniel Tracy, Kathryn Anastos, Mardge Cohen, Elizabeth T Golub, Roksana Karim and 7 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Impaired bisecting GlcNAc reprogrammed M1 polarization of macrophage.Cell communication and signaling : CCS · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

Iftach ShakedFrom the Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA (I.S., K.L.); Department of Epidemiology & Population Health, Department of Medicine (D.B.H., D.T., K.A., R.K.), and Department of Obstetrics & Gynecology and Women's Health (K.A.), and Department of Microbiology & Immunology (V.P.), Albert Einstein College of Medicine, Bronx, NY; Department of Immunology/Microbiology, Rush University, Chicago, IL (J.P., M.C., A.L.L.); Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.T.G.); Division of Infectious Disease, Georgetown University Medical Center, Washington, DC (M.A.Y.); Department of Cardiovascular Disease, SUNY Downstate Medical Center, Brooklyn, NY (J.L.); Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA (R.K.); Department of Medicine, University of California, San Francisco (P.C.T.); Department of Cardiology, Angiology and Pneumonology, University of Heidelberg, Germany (C.G.); and Department of Medicine, University of California, San Diego (B.M.).
David B Hanna
Christian Gleißner
Brenda Marsh
Jill Plants
Daniel Tracy
Kathryn Anastos
Mardge Cohen
Elizabeth T Golub
Roksana Karim
Jason Lazar
Vinayaka Prasad
Phyllis C Tien
Mary A Young
Alan L Landay
Robert C Kaplan
Klaus Ley
Rush University · USUniversity of Southern California · USGeorgetown University Medical Center · USHeidelberg University · DELa Jolla Institute for Immunology · USSUNY Downstate Health Sciences University · USGeorgetown University · USJohns Hopkins University · USUniversity of California, San Francisco · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Emory WIHS CRS - Longitudinal CohortU01AI103408 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, WINGOOD, GINA MARIA · 2013 to 2018
$14.1M
UAB-MISS WIHS CohortU01AI103401 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KEMPF, MIRJAM-COLETTE, KONKLE-PARKER, DEBORAH J · 2013 to 2018
$11.2M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000454NHLBI NIH HHS R01 HL083760NHLBI NIH HHS R01-HL-083760NHLBI NIH HHS R01 HL095140NHLBI NIH HHS R01-HL-095140NHLBI NIH HHS R01 HL115232NIAID NIH HHS U01 AI031834NIAID NIH HHS U01-AI-031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01-AI-034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01-AI-034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01-AI-034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01-AI-035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01-AI-103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01-AI-103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01-AI-103401NIAID NIH HHS U01 AI103408NIAID NIH HHS U01-AI-103408NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD-032632NIDDK NIH HHS P30 DK026743NIMH NIH HHS R01 MH083579
6 · The paper itself

Abstract

objectiveInfection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) may be associated with atherosclerosis and vascular disease. Macrophages are a major component of atherosclerotic plaque, and classically activated (M1) macrophages contribute to plaque instability. Our goal was to identify plasma biomarkers that reflect macrophage inflammation and are associated with subclinical atherosclerosis. APPROACH AND

resultsWe tested whether M1 macrophages produce galectin-3-binding protein in vitro. Then, we measured galectin-3-binding protein and the soluble macrophage biomarkers soluble cluster of differentiation (CD) 163 and soluble CD14 in 264 participants in the Women's Interagency HIV Study. Women were positive for HIV, HCV, both, or neither (66 in each group, matched for age, race/ethnicity, and smoking status). Carotid artery disease was assessed by ultrasound measurement of right distal common carotid artery intima-media thickness, distensibility, and presence of atherosclerotic lesions (intima-media thickness >1.5 mm). Plasma galectin-3-binding protein was higher in HCV+ than HCV- women (P<0.01) but did not differ by HIV status. The 3 inflammatory macrophage markers were significantly correlated with each other and negatively correlated with CD4+ counts in HIV-infected women. We defined a macrophage score as 1, 2, or 3 biomarkers elevated above the median. In models adjusted for traditional risk factors, higher macrophage scores were significantly associated with increased atherosclerotic lesions and lower carotid distensibility. Receiver-operator curve analysis of lesions revealed that the markers added predictive value beyond traditional risk factors and C-reactive protein.

conclusionsThe macrophage inflammatory markers galectin-3-binding protein, soluble CD163, and soluble CD14 are significantly associated with carotid artery disease in the setting of HIV and HCV infection.

Indexed as

CoinfectionAdultAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, NeoplasmAsymptomatic DiseasesBiomarkersBiomarkers, TumorCarotid Artery DiseasesCarotid Intima-Media ThicknessCarrier ProteinsCD163 AntigenCross-Sectional StudiesExtracellular Matrix ProteinsFemaleGlycoproteinsAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkersBiomarkers, TumorCarrier ProteinsCD163 AntigenExtracellular Matrix ProteinsGlycoproteinsInflammation MediatorsLGALS3BP protein, humanLipopolysaccharide ReceptorsReceptors, Cell Surfaceacquired immunodeficiency syndromeatherosclerosisimmune systemrisk factorswomen

Identifiers

PMID24651679
PMCPMC4067091
OpenAlexW2091080239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.